Revance to Participate in Upcoming Investor Conferences
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and
therapeutic indications, today announced that the company will participate in two upcoming investor conferences.
Revance management is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA on Tuesday,
March 7 at 10:00am ET.
Revance management is also scheduled for a fireside chat at the Barclays Capital Global Healthcare Conference 2017 in Miami, FL
on Tuesday, March 14 at 3:20pm ET.
Interested parties can access the live audio webcast for both of these conferences from the Investor Relations section of the
company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for
approximately 30 days.
About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company
is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology,
orthopedics and neurology. Revance’s science is based upon a proprietary peptide technology, which when combined with active drug
molecules, may help address current unmet needs. Revance’s initial focus is on developing DaxibotulinumtoxinA, the company’s highly
purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle
movement disorders.
The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of
glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neurotoxin. The company
holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of its proprietary
peptide technology platform. More information on Revance may be found at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
Investors:
Revance Therapeutics
Jeanie Herbert, 714-325-3584
jherbert@revance.com
or
Burns McClellan
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com
or
Trade Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170222006396/en/